| RENAL CELL CARCINOMA

| Epidemiology in general population
In the United States, the lifetime risk of renal cancers is 1.62%, with the annual incidence steadily increasing during the past several years. 8 Renal cancers are more common in developed nations than in developing nations (age-standardized incidence of 9.2 vs 2.6 per 100 000). 9 More than 85% of kidney cancers are defined as RCCs, with 25% of patients presenting with advanced disease (locally invasive or metastatic disease). Roughly 10% to 30% of patients who undergo resection for local disease will have recurrence, and the median survival for patients with metastatic disease is 13 months. 10, 11 The majority of RCCs are now identified incidentally on radiographic imaging performed for other diagnostic reasons as common presenting symptoms can be nonspecific (eg, fatigue, weight loss, anemia). 10 Risk factors for RCC in the general population include male sex, African ancestry, obesity, tobacco use, chronic kidney disease (CKD), viral hepatitis, and hypertension. 12 Prognosis is closely correlated with the stage of RCC: stage I: tumor less than 7 cm in greatest dimension and limited to the kidney, 5-year survival 95%; stage II: tumor greater than 7 cm in greatest dimension and limited to the kidney, 5-year survival 88%;
stage III: tumor in major veins or adrenal gland, tumor within Gerota fascia, or 1 regional lymph node involved, 5-year survival 59%; and stage IV: tumor beyond Gerota fascia or more than 1 regional lymph node involved, 5-year survival 20%.
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There are 5 distinct types of RCC. Clear cell RCC accounts for nearly 75% of all RCCs. 10 Clear cell RCC is seen in von Hippel-Lindau disease, in which RCCs arise from the inactivation of the remaining normal VHL allele. Defects in the VHL gene also account for approximately 60% of cases of sporadic clear cell RCC. 13 Papillary RCC represents the second most common type of RCC (~12%). Genetic mutations in MET, TFE3, and FH have been associated with sporadic and inherited forms of papillary RCC. Localized papillary RCC metastasizes less frequently than clear cell RCC
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; however, survival is significantly worse for metastatic papillary compared with metastatic clear cell RCC. 15 Less common types of RCC include chromophobe (4%), collecting duct (<1%), and those that are of an unspecified type. 
| Epidemiology in ESRD population
Data from the US Renal Data System (USRDS) linked to Medicare claims for patients receiving dialysis during 1997 through 2005 indicate the incidence of RCC among patients with ESRD to be 5.2/1000
person-years at risk. 16 Male sex, increasing age, African ancestry, acquired cystic kidney disease (ACKD), and ESRD due to tuberous sclerosis, focal segmental glomerulosclerosis, or obstruction all increased the risk of RCC; interestingly, in this cohort, smoking was not associated with increased RCC risk, nor did dialysis modality influence risk. 16 Longer dialysis duration also increases the risk of renal cancers, 17 and some data suggest the risk may be bimodal, peaking in the first year after dialysis initiation and then again in years 4 through 16 ACKD develops within 3 to 7 years of initiating dialysis, with an associated 1.6-7.0% incidence of RCC. 16 Fortunately, RCCs tend to be smaller, lower stage, and lower grade among patients with ESRD compared with the general population, therefore early screening, detection, and treatment is associated with cure. 21, 22 Although surveillance remains a controversial topic, some have suggested that routine screening begin 3 years after initiation of dialysis to encourage early identification of these tumors. 16 
| Epidemiology in transplant population
To assess the cancer risk of patients receiving renal replacement ther- 24 The study compared intervals with nonfunctional kidneys (time on waitlist or after allograft failure; requires dialysis) with intervals with functional kidneys (time immediately after transplantation; requires immunosuppression). The posttransplantation group had higher incidence of Kaposi sarcoma, lymphomas, and skin cancers but lower incidences of thyroid and renal cancers. 24 In addition, the rarity of RCC in the allograft compared with native kidneys suggests that an intrinsic factor within the native kidneys may be contributing to the higher incidence. 27, 29 In fact, autosomal dominant polycystic kidney disease (ADPKD) has been described as a risk factor for RCC development, with these patients having a 2 to 3 times higher risk of RCC compared with the general ESRD population
38
; in contrast, among patients transplanted for ESRD secondary to ADPKD, the risk of RCC is lower than that among patients transplanted for other disease etiologies. 39 Taken together, these data suggest that posttransplantation immunosuppression may not increase the risk for RCC among transplant recipients. 
| RCC management pre-kidney transplantation
Approximately 5% of patients on the waitlist will have RCC at the time of transplantation. 47 Denton et al examined specimens from native nephrectomy at the time of transplantation in asymptomatic patients with ESRD. 48 In their sample of 260 kidneys, 33% had ACKD, 14% had renal adenomas, and 4.2% had RCC at the time of transplantation. 48 Similarly, a series of 258 ipsilateral nephrectomies at the time of transplantation identified RCC in 12 (4.7%). There was no significant difference in graft function or patient survival posttransplantation; however, 2 (25%) patients developed contralateral RCC. 49 The high incidence of RCC diagnosed in the first 6 to 12 months after transplantation suggests that many recipients have preexisting Guidelines from the Canadian Society of Transplantation recommend that (1) patients with small (<5 cm), incidental tumors require no waiting period, (2) patients with a past history of symptomatic RCC wait at least 2 years from treatment to transplantation; and (3) patients with large (≥5 cm) or invasive RCC wait at least 5 years from treatment to transplantation. 54 
| Use of kidneys with RCC for transplantation
The demand for kidneys continues to far exceed the supply of donor organs and, as such, consideration for the use of kidneys from donors with cancer is warranted. 1 The risk of contralateral RCC in the general population is estimated to be 0.4% at 10 years and 0.8% at 20 years, suggesting that contralateral kidneys of donors with solitary renal tumors may be an underused source of allografts. 
| RCC management post-kidney transplantation
Posttransplantation cancer diagnosis has a negative effect on patient mortality while escalating health care costs; the diagnosis of solid organ cancers within 3 years of transplantation triples 3-year mortality. 59 Cancer diagnosis within a similar time frame was associated with a $14 500 to $18 000/year increase in inpatient billing and a $8000 to $9000/year increase in outpatient billing. 59 Studies have found the risk of RCC over time posttransplantation to be biphasic:
risk is high immediately posttransplantation, declines until 2.5 years posttransplantation, then steadily increases with second peak at 4 to 15 years. 7, 25, 27 Understanding the variation in cancer risk after kidney transplantation may help guide screening and contain costs. The 5-and 10-year cancer-specific survival rates for RCC are 71% and 58%, respectively. 85) . 72 Similarly, a retrospective study of the Organ Procurement and Transplantation Network database found that the incidence rates at 2.6 years for de novo malignancy were 0% for sirolimus/everolimus, 0.47% for sirolimus/everolimus plus a CNI, and 1.0% for a CNI alone. 73 Multivariate analysis revealed that mTOR inhibitors were associated with a 60% reduction in all posttransplantation malignancies and a 55% reduction in solid posttransplantation malignancies. 73 A prospective trial by the CONVERT study group randomized 830 renal transplant recipients to continue CNI-based therapy or switch to sirolimus-based therapy. 74 After 2 years of therapy, the sirolimus group had a lower rate of malignancy compared with the CNI group (2.1 vs 6.0 malignancies per 100 person-years of exposure).
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The ZEUS study compared cyclosporine-and everolimus-based therapies and found a higher rate of malignancy in the cyclosporine group (6.4%) compared with everolimus (1.6%). 75 However, several other studies with shorter follow-up have failed to show any difference. 
| RCC screening post-renal transplantation
Renal ultrasound is an inexpensive, noninvasive test for the diagnosis of RCC in renal transplant recipients, with a positive predictive value of 100% and a negative predictive value of 94%. 84, 85 ; only the ERBP guidelines recommend native kidney ultrasound as RCC screening in kidney transplant recipients. 86 The EAU recommends annual ultrasound of native kidneys and allograft for anyone with ACKD, previous RCC, or von Hippel-Lindau disease. 50 Goh et al recommended screening ultrasound every 2 years for patients with ACKD and every 5 years for recipients without ACKD. 46 Frasca et al proposed annual screening ultrasound for patients with ADPKD or ACKD and every 2 years for patients older than 60 years who had been receiving dialysis longer than 5 years before transplantation.
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Screening in the posttransplantation population could be problematic secondary to overdetection and/or overtreatment of clinically insignificant disease. 88 Standard RCC treatment (reduction in immunosuppression or surgical resection) can be potentially harmful to the allograft, and patient life expectancy must be taken into account. Other potential adverse effects of screening include discomfort, potential radiation exposure, need for invasive follow-up tests, financial burden, inconvenience, and anxiety. 88 There are no prospective data on RCC screening cost-effectiveness in the transplant or general populations. 83 However, Markov decision modeling suggests that biennial ultrasound screening in the renal transplant population would cost $252 100/life-year saved; focusing on high-risk subpopulations could improve the incremental cost-effectiveness ratio. 89 As there is no consensus, more research is needed to identify the ideal surveillance for different populations.
| UROTHELIAL CARCINOMA AND BLADDER CANCER
| Epidemiology in general population
The annual incidence of bladder cancer in the general population is 0.02%, and the incidence of UC (also known as transitional cell carcinoma) varies with geography. 
| Epidemiology in transplant population
The risk of bladder cancer is increased in patients with ESRD, but the magnitude is not as great as for RCC; SIRs for bladder cancer from the USRDS, EDTA, and ANZDATA were 1.4 (1.3-1.5), 1. clinical manifestations, such as nephropathy, hemorrhagic cystitis, ureteral stenosis, and malignancy. 95, 96 At the time of diagnosis, the virus is most commonly localized to the renal calyces, renal pelvis, ureters, and bladder. 97 A review of population studies found viruria in 29% and viremia in 11% of renal transplant recipients. 98 For virus-associated malignancies, such as BKV nephropathy, reduction in immunosuppression should be considered.
While there is an association between BKV and carcinogenesis in rodent models, the evidence of BKV as the etiology for human malignancies is limited. 99 The presence of viruria in transplant recipients has been associated with a 5-fold increase in UC compared with patients without BKV. In these cases, radical nephroureterectomy should be considered.
Unlike RCC, duration of dialysis was not a risk factor for the development of UC. Graft function was equivalent at the time of last follow-up for the UC group (72%) compared with controls (68%).
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The risk of contralateral UC in posttransplantation patients who have previously undergone unilateral laparoscopic nephroureterectomy is high. In a small series, 5 of 12 patients had UC in the contralateral kidney after prophylactic nephroureterectomy. 32 Shiels et al also demonstrated that transplant recipients were more likely to be diagnosed with regional (odds ratio 1.42) or distant disease (odds ratio 1.80) than was the general population. 32 The median time from transplantation to diagnosis was 4.5 years. The relatively short interval from transplantation to cancer diagnosis may be related to the intensity of immunosuppression, suggesting that malignancy risk may decrease with time as immunosuppression is weaned. 32 Stage-stratified, disease-specific survival was equal for stage I/II tumors but significantly worse for stage III/IV bladder cancer compared with controls. 32 The 5-and 10-year cancer-specific survival rates in transplant patients with UC were 50% and 0%, respectively. 60 UC is rarely found in the transplanted kidney, and the allograft can often be preserved during treatment. However, there are case reports of allograft malignancies requiring either local resection and reconstruction or nephroureterectomy and lymphadnectomy. [111] [112] [113] One of the largest series detailing treatment of bladder cancer after kidney transplantation followed standard therapy despite immunosuppression: intravesical BCG [live attenuated bacteria and works through immunomodulation and therefore has 2 implications in the transplant population: (i) may be less effective in someone receiving immunosuppression and (ii) immunosuppressed patients may be at higher risk for BCG complication including sepsis] for noninvasive tumors and radical cystoprostatectomy with lymphadenectomy and urinary diversion for invasive tumors. 114 Reconstruction with an ileal neobladder is also an option, though avoided by some because of immunosuppression and abnormal pelvic anatomy. 115 Small series have shown preservation of graft function after resection of invasive cancer.
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No standard of care has been established for the management of immunosuppression after treatment of UC, although no change in regimen may be appropriate with localized UC. 117 Literature on the optimal adjuvant chemotherapeutic regimen in these patients is sparse; a small study of 22 renal transplant patients with locally advanced UC compared surgery alone to surgery followed by gemcitabine and cisplatin. 105, 106 The surgery-plus-chemotherapy group had a longer mean survival time compared with the surgery-alone group (31 vs 14 months) but a higher incidence of hematologic toxicities requiring dose reduction. 105 Transplantation society guidelines do not specifically recommend screening transplant recipients for UC.
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| CONCLUSIONS
Urologic cancers in kidney transplantation are an important cause of morbidity and mortality in this population. Routine screening in transplant recipients would allow for earlier diagnosis and management of these potentially lethal malignancies. However, there is no consensus for posttransplantation RCC screening, as data are limited.
Prospective studies to determine the best cancer screening methods and intervals are urgently needed.
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